Tim Beyers

See you soon, Fools.

Fool on!

When are broken breakers worth buying?

We break it down.

You're listening to Motley Fool Money.

Welcome, Fools.

I'm your host, Tim Byers.

And with me, our longtime Rule Breakers teammates and old friends, Rick Benares and Carl Thiel.

It's a Gen X Power Half Hour.

Today, we're talking about our favorite broken breakers, innovators that have yet to convince the market of their long-term potential.

Carl, Rick, we've got a lot to talk about.

But first, Carl, since we've got you here, I'd love to take just a couple of minutes to talk about the

federal layoffs and any potential consequences you see for the biotech industry.

And for those who haven't been following along, this relates to federal cuts having to do with CDC and related health and human services agencies.

Carl, what do you see in here and what should we pay attention to as biotech investors?

Just a quick follow-up on this, and then we'll move on.

I think what I'm hearing from you is that there are some short-term disruptions here, but we like early-stage biotechs in Rule Breakers.

You're the one that brings us most of these.

This does not sound like something that over the long term should dissuade us from getting interested in emergent science in biotech.

There's going to be maybe some short-term disruptions.